Abstract |
The hepatitis C virus (HCV) has been cloned, and assays capable of detecting antibody to HCV recombinant proteins (anti-HCV) have been developed. Concurrent with the cloning and development of the anti-HCV screening tests, trials with interferon alfa-2b have documented biochemical and histologic improvement in the indices of hepatitis C and non-A, non-B (NANB) in patients who were chronically infected. Subsequently, the anti-HCV assays and interferon alfa-2b have become clinically available. These new detection and treatment modalities can now be used in the management of hemophilics and other chronically transfused patients who bear great risk for blood-borne infections and manifest signs of chronic hepatitis.
|
Authors | L M Aledort |
Journal | American journal of hematology
(Am J Hematol)
Vol. 44
Issue 1
Pg. 29-37
(Sep 1993)
ISSN: 0361-8609 [Print] United States |
PMID | 8342562
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Review)
|
Topics |
- Chronic Disease
- Hematology
- Hepatitis C
(complications, diagnosis, therapy)
- Humans
|